Analysis Mineralys Therapeutics, Inc. (MLYS)
6/4/2024
Analysis of Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS) has shown some fluctuations in its stock price recently. The Relative Strength Index (RSI) values have been hovering around the mid-range, indicating a balanced market sentiment without any extreme overbought or oversold conditions.The Moving Average Convergence Divergence (MACD) indicator has been negative, suggesting a bearish trend in the stock price. The MACD histogram has also been negative, indicating a potential continuation of the bearish momentum.
The Moving Average (MA) indicator has been slightly below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) values, which could suggest a short-term bearish outlook.
Overall, based on the recent data, Mineralys Therapeutics, Inc. may be experiencing some downward pressure in its stock price. Investors should closely monitor the MACD and moving average indicators for potential trend reversals or confirmations of the current bearish trend.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight increase in growth rate expected in the near future compared to the current period. However, the projected growth rates for the next year and the next 5 years are lower than the average growth rate achieved in the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of estimates, from a low of $164 to a high of $275, indicating some uncertainty in the market.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and healthy return on assets and equity. The balance sheet shows a decent current ratio, but a relatively high total debt to equity ratio. The income statement indicates significant revenue and EBITDA, with a good gross profit margin and diluted EPS.
Stock statistics reveal details such as short ratio, float shares, shares outstanding, and insider and institutional ownership percentages. Valuation metrics include PEG ratio, PE ratios, enterprise value, price to book, price to sales, and market capitalization. The stock price summary provides information on beta, moving averages, and the 52-week price range.
Lastly, dividends and splits data show dividend rates, payout ratio, dividend yield, and historical split information.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing over the years, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA ranging from $81 billion to $129 billion.
7. Despite fluctuations in other income and expenses, the company has been able to generate consistent income from its core operations.
8. The company has managed its operating expenses effectively, with a slight increase over the years but not at a rate higher than the revenue growth.
9. The company has been able to generate positive non-operating interest income, contributing to its overall profitability.
10. The number of basic and diluted shares outstanding has remained relatively stable over the years.
Overall, the financial performance of the company has been positive, showing growth in sales, income, and profitability metrics.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. Looking ahead to the next quarter ending on September 30, 2024, analysts project an average EPS of $1.42, ranging from a low estimate of $1.33 to a high estimate of $1.51. This is higher than the EPS of $1.35 reported in the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This represents growth from the EPS of $5.67 in the previous fiscal year.
4. Looking further ahead to the next fiscal year ending on September 30, 2025, analysts anticipate an average EPS of $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This shows a potential increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
MACD of MLYS
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
